Association among clinical characteristics, geriatric assessment measures, and OS in older adults who received postremission therapy for AML (N = 40)
| Characteristics . | HR for mortality (95% CI) . | |||
|---|---|---|---|---|
| Unadjusted . | P . | Adjusted* . | P . | |
| Clinical and demographic characteristics | ||||
| Age (per 1-y difference) | 1.02 (0.97-1.08) | .402 | ||
| Sex (female vs male) | 1.77 (0.87-3.58) | .115 | ||
| ECOG performance status (>1 vs 2-3)† | 1.59 (0.76-3.33) | .223 | ||
| Hemoglobin (per 1 g/dL difference) | 0.94 (0.71-1.25) | .666 | ||
| Lactate dehydrogenase (≥600 vs <600 U/L) | 1.00 (0.99-1.00) | .868 | ||
| White blood cell count (≥25 000 vs <25 000) | 1.00 (0.99-1.02) | .246 | ||
| Creatinine (>1.3 vs ≤1.3 g/dL) | 1.42 (0.58-3.48) | .446 | ||
| Cytogenetic risk group (favorable/intermediate vs unfavorable)‡ | 0.53 (0.24-1.20) | .128 | ||
| Initial cycle of consolidative treatment | ||||
| Cytarabine (vs other) | 0.97 (0.34-2.82) | .958 | ||
| Hypomethylating agent (vs other) | 1.44 (0.36-5.83) | .606 | ||
| Hematopoietic stem cell transplantation (no vs yes) | 1.48 (0.63-3.44) | .367 | ||
| Prior myelodysplastic syndrome (no vs yes) | 0.57 (0.23-1.38) | .212 | ||
| Postremission geriatric assessment measures | ||||
| Cognitive impairment (Modified Mini-Mental State Exam (<77 vs ≥77) | 0.61 (0.23-1.60) | .316 | ||
| Depressive symptoms (CES-D ≥16 vs <16)‡ | 2.43 (1.10-5.37) | .028 | 2.46 (1.11-5.44) | .027 |
| Distress (score ≥4 vs <4)‡ | 1.64 (0.80-3.36) | .176 | ||
| Instrumental ADL impairment (yes vs no) | 1.46 (0.71-2.99) | .305 | ||
| ADL impairment (yes vs no) | 0.78 (0.39-1.58) | .495 | ||
| Mobility impairment (yes vs no) | 1.65 (0.63-4.31) | .307 | ||
| Impaired physical performance (SPPB <9 vs ≥9) | 2.42 (1.08-5.42) | .031 | 2.66 (1.19-5.97) | .018 |
| Impairment in grip strength (<26 kg in men and <16 kg in women) | 1.76 (0.67-4.57) | .250 | ||
| Medications ≥5 | 1.46 (0.56-3.81) | .441 | ||
| Comorbidity burden (HCT-CI >2 vs ≤2) | 1.97 (0.98-3.94) | .056 | ||
| Characteristics . | HR for mortality (95% CI) . | |||
|---|---|---|---|---|
| Unadjusted . | P . | Adjusted* . | P . | |
| Clinical and demographic characteristics | ||||
| Age (per 1-y difference) | 1.02 (0.97-1.08) | .402 | ||
| Sex (female vs male) | 1.77 (0.87-3.58) | .115 | ||
| ECOG performance status (>1 vs 2-3)† | 1.59 (0.76-3.33) | .223 | ||
| Hemoglobin (per 1 g/dL difference) | 0.94 (0.71-1.25) | .666 | ||
| Lactate dehydrogenase (≥600 vs <600 U/L) | 1.00 (0.99-1.00) | .868 | ||
| White blood cell count (≥25 000 vs <25 000) | 1.00 (0.99-1.02) | .246 | ||
| Creatinine (>1.3 vs ≤1.3 g/dL) | 1.42 (0.58-3.48) | .446 | ||
| Cytogenetic risk group (favorable/intermediate vs unfavorable)‡ | 0.53 (0.24-1.20) | .128 | ||
| Initial cycle of consolidative treatment | ||||
| Cytarabine (vs other) | 0.97 (0.34-2.82) | .958 | ||
| Hypomethylating agent (vs other) | 1.44 (0.36-5.83) | .606 | ||
| Hematopoietic stem cell transplantation (no vs yes) | 1.48 (0.63-3.44) | .367 | ||
| Prior myelodysplastic syndrome (no vs yes) | 0.57 (0.23-1.38) | .212 | ||
| Postremission geriatric assessment measures | ||||
| Cognitive impairment (Modified Mini-Mental State Exam (<77 vs ≥77) | 0.61 (0.23-1.60) | .316 | ||
| Depressive symptoms (CES-D ≥16 vs <16)‡ | 2.43 (1.10-5.37) | .028 | 2.46 (1.11-5.44) | .027 |
| Distress (score ≥4 vs <4)‡ | 1.64 (0.80-3.36) | .176 | ||
| Instrumental ADL impairment (yes vs no) | 1.46 (0.71-2.99) | .305 | ||
| ADL impairment (yes vs no) | 0.78 (0.39-1.58) | .495 | ||
| Mobility impairment (yes vs no) | 1.65 (0.63-4.31) | .307 | ||
| Impaired physical performance (SPPB <9 vs ≥9) | 2.42 (1.08-5.42) | .031 | 2.66 (1.19-5.97) | .018 |
| Impairment in grip strength (<26 kg in men and <16 kg in women) | 1.76 (0.67-4.57) | .250 | ||
| Medications ≥5 | 1.46 (0.56-3.81) | .441 | ||
| Comorbidity burden (HCT-CI >2 vs ≤2) | 1.97 (0.98-3.94) | .056 | ||